National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions

K.V. Juul, V O Thomsen, A. Nissen, J Hallas, H J Kolmos, P. Funch-Jensen, K Lauritsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND: We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).

METHODS: All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified. So were all outpatients receiving a drug prescription for H. pylori eradication.

RESULTS: We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients. The incidence of new consumers was 220 per 10(5) inhabitants per year, with a maximum at 70-79 years of age. Eighty-six per cent of the patients had only one treatment course. In 16% of the eradication therapies, nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45% had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy. Consumption of antibiotics used for H. pylori eradication accounted for 1.4% of the total consumption of antibiotics.

CONCLUSIONS: The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used. Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.

OriginalsprogEngelsk
BogserieScandinavian Journal of Gastroenterology. Supplement
Vol/bind33
Udgave nummer9
Sider (fra-til)928-32
Antal sider5
ISSN0036-5521
StatusUdgivet - sep. 1998

Fingeraftryk

Denmark
Helicobacter pylori
Prescriptions
Incidence
Pharmaceutical Preparations
Outpatients
Databases

Citer dette

@article{6d46b6e161e64683a80bbecadcd3aa47,
title = "National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions",
abstract = "BACKGROUND: We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).METHODS: All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified. So were all outpatients receiving a drug prescription for H. pylori eradication.RESULTS: We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients. The incidence of new consumers was 220 per 10(5) inhabitants per year, with a maximum at 70-79 years of age. Eighty-six per cent of the patients had only one treatment course. In 16{\%} of the eradication therapies, nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45{\%} had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy. Consumption of antibiotics used for H. pylori eradication accounted for 1.4{\%} of the total consumption of antibiotics.CONCLUSIONS: The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used. Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Amoxicillin, Antacids, Anti-Bacterial Agents, Bismuth, Child, Denmark, Drug Prescriptions, Drug Therapy, Combination, Female, Health Care Surveys, Helicobacter Infections, Helicobacter pylori, Histamine H2 Antagonists, Humans, Imidazoles, Macrolides, Male, Middle Aged, Penicillins, Proton Pump Inhibitors, Tetracyclines, Journal Article",
author = "K.V. Juul and Thomsen, {V O} and A. Nissen and J Hallas and Kolmos, {H J} and P. Funch-Jensen and K Lauritsen",
year = "1998",
month = "9",
language = "English",
volume = "33",
pages = "928--32",
journal = "Scandinavian Journal of Gastroenterology. Supplement",
issn = "0085-5928",
publisher = "Taylor & Francis",
number = "9",

}

National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. / Juul, K.V.; Thomsen, V O; Nissen, A.; Hallas, J; Kolmos, H J; Funch-Jensen, P.; Lauritsen, K.

I: Scandinavian Journal of Gastroenterology. Supplement, Bind 33, Nr. 9, 09.1998, s. 928-32.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions

AU - Juul, K.V.

AU - Thomsen, V O

AU - Nissen, A.

AU - Hallas, J

AU - Kolmos, H J

AU - Funch-Jensen, P.

AU - Lauritsen, K

PY - 1998/9

Y1 - 1998/9

N2 - BACKGROUND: We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).METHODS: All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified. So were all outpatients receiving a drug prescription for H. pylori eradication.RESULTS: We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients. The incidence of new consumers was 220 per 10(5) inhabitants per year, with a maximum at 70-79 years of age. Eighty-six per cent of the patients had only one treatment course. In 16% of the eradication therapies, nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45% had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy. Consumption of antibiotics used for H. pylori eradication accounted for 1.4% of the total consumption of antibiotics.CONCLUSIONS: The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used. Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.

AB - BACKGROUND: We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).METHODS: All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified. So were all outpatients receiving a drug prescription for H. pylori eradication.RESULTS: We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients. The incidence of new consumers was 220 per 10(5) inhabitants per year, with a maximum at 70-79 years of age. Eighty-six per cent of the patients had only one treatment course. In 16% of the eradication therapies, nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45% had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy. Consumption of antibiotics used for H. pylori eradication accounted for 1.4% of the total consumption of antibiotics.CONCLUSIONS: The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used. Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Amoxicillin

KW - Antacids

KW - Anti-Bacterial Agents

KW - Bismuth

KW - Child

KW - Denmark

KW - Drug Prescriptions

KW - Drug Therapy, Combination

KW - Female

KW - Health Care Surveys

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Histamine H2 Antagonists

KW - Humans

KW - Imidazoles

KW - Macrolides

KW - Male

KW - Middle Aged

KW - Penicillins

KW - Proton Pump Inhibitors

KW - Tetracyclines

KW - Journal Article

M3 - Journal article

C2 - 9759947

VL - 33

SP - 928

EP - 932

JO - Scandinavian Journal of Gastroenterology. Supplement

JF - Scandinavian Journal of Gastroenterology. Supplement

SN - 0085-5928

IS - 9

ER -